GoAI
Get started
Liquidia Corporation logo

Liquidia Corporation

LQDA

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Previous close

$68.62

−$2.43 · -3.42%

Aug 21, 4:00 PM ET

Pre-market

$68.945

+$0.325 · +0.47%

Aug 24, 8:06 AM ET

LQDA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

87

Deep Value

Momentum

71

Gaining

Sentiment

47

Mixed

Risk resilience

63

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
US
CEO
Roger A. Jeffs
Listed since
Jul 26, 2018
Employees
216

Market position

Day range

Current $68.62

52-week range

Current $68.62

Open
$70.63
Previous close
$71.05
Volume
1.7M
0.94× average
Average volume
1.81M
Average daily volume
Market cap
6.1B USD
Beta
0.57
Market reference 1
50-day average
$79.1452
-13.30% below average
200-day average
$49.2606
+39.30% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.98B USD
P/E (TTM)
43.73×
P/B (TTM)
31.26×
P/S (TTM)
13.53×
EV / EBITDA
-68.84×
Earnings yield
-2.32%
Free cash flow yield
-1.35%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
92.48%
Operating margin
37.39%
Net margin
30.74%
Return on equity
-154.03%
Return on assets
-21.02%
Return on invested capital
-20.46%

Financial health

Debt / equity
0.66×
Current ratio
1.4×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends194%-215%-625%-1034%Gross margin, FY2021: 76.48%Gross margin, FY2022: 82.06%Gross margin, FY2023: 83.49%Gross margin, FY2024: 58.00%Gross margin, FY2025: 91.64%Operating margin, FY2021: -262.95%Operating margin, FY2022: -243.30%Operating margin, FY2023: -419.62%Operating margin, FY2024: -866.63%Operating margin, FY2025: -32.45%Net margin, FY2021: -269.03%Net margin, FY2022: -257.39%Net margin, FY2023: -448.89%Net margin, FY2024: -931.65%Net margin, FY2025: -43.53%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 76.48%. Gross margin FY2022 82.06%. Gross margin FY2023 83.49%. Gross margin FY2024 58.00%. Gross margin FY2025 91.64%. Operating margin FY2021 -262.95%. Operating margin FY2022 -243.30%. Operating margin FY2023 -419.62%. Operating margin FY2024 -866.63%. Operating margin FY2025 -32.45%. Net margin FY2021 -269.03%. Net margin FY2022 -257.39%. Net margin FY2023 -448.89%. Net margin FY2024 -931.65%. Net margin FY2025 -43.53%.

Income trends

Revenue

158.32M USD+1031.18%

Operating income

−51.38M USD+57.64%

Net income

−68.92M USD+47.14%
Income trends across reported periods187.19M USD71.71M USD−43.78M USD−159.27M USDRevenue, FY2021: 12.85M USDRevenue, FY2022: 15.94M USDRevenue, FY2023: 17.49M USDRevenue, FY2024: 14M USDRevenue, FY2025: 158.32M USDOperating income, FY2021: −33.8M USDOperating income, FY2022: −38.77M USDOperating income, FY2023: −73.38M USDOperating income, FY2024: −121.29M USDOperating income, FY2025: −51.38M USDNet income, FY2021: −34.58M USDNet income, FY2022: −41.02M USDNet income, FY2023: −78.5M USDNet income, FY2024: −130.39M USDNet income, FY2025: −68.92M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.85M USD. Revenue FY2022 15.94M USD. Revenue FY2023 17.49M USD. Revenue FY2024 14M USD. Revenue FY2025 158.32M USD. Operating income FY2021 −33.8M USD. Operating income FY2022 −38.77M USD. Operating income FY2023 −73.38M USD. Operating income FY2024 −121.29M USD. Operating income FY2025 −51.38M USD. Net income FY2021 −34.58M USD. Net income FY2022 −41.02M USD. Net income FY2023 −78.5M USD. Net income FY2024 −130.39M USD. Net income FY2025 −68.92M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue158.32M USD14M USD17.49M USD15.94M USD12.85M USD
Cost of goods sold13.24M USD5.88M USD2.89M USD2.86M USD3.02M USD
Gross profit145.08M USD8.12M USD14.6M USD13.08M USD9.83M USD
Research and development39.28M USD47.84M USD43.24M USD19.44M USD20.52M USD
Selling, general, and administrative157.18M USD81.57M USD44.74M USD32.41M USD23.11M USD
Operating expenses196.45M USD129.41M USD87.98M USD51.85M USD43.63M USD
Interest income6.62M USD7.65M USD3.47M USD1.09M USD33K USD
Interest expense24.17M USD12.49M USD6.27M USD2.34M USD762K USD
Depreciation and amortization1.53M USD2.2M USD2.18M USD3.65M USD5.61M USD
Operating income−51.38M USD−121.29M USD−73.38M USD−38.77M USD−33.8M USD
Net income−68.92M USD−130.39M USD−78.5M USD−41.02M USD−34.58M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

7 ratings
Strong buy114%
Buy571%
Hold00%
Sell114%
Strong sell00%

LQDA news

gurufocus.com

Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors

On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend from its 52-week high of $93.61, while still reflecting a subst

Read source
zacks.com

Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Read source
defenseworld.net

Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA

Handelsbanken Fonder AB bought a new stake in Liquidia Corporation (NASDAQ: LQDA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The…

Read source
zacks.com

LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

Read source
fool.com

Why Liquidia Stock Was Diving This Week

The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.

Read source
zacks.com

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Read source

LQDA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LQDA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
332.02M
Weight
0.29%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
190.65M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
127.77M
Weight
0.16%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
68.02M
Weight
0.07%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares S&P Small-Cap 600 Growth ETF logoiShares S&P Small-Cap 600 Growth ETFIJT
Market value
50.52M
Weight
0.60%
AUM
8.22B USD
Expense ratio
0.18%
Price / 1D
$173.9+0.61%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
46.91M
Weight
0.28%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
46.61M
Weight
0.31%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
33.31M
Weight
0.19%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research LQDA

research.disclaimer